MedDataX Logo

Effects of Acute Systemic Inflammation on Arterial Stiffness and Microcirculation.

NCT ID: NCT01556373

Last Updated: 2019-12-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

8 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-02-23

Study Completion Date

2015-04-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to assess the effect of acute inflammation on arterial stiffness and microcirculation. Patients with severe sepsis will be compared with age-, sex- and cardiovascular risk factors-matched controls.

The primary outcome is the carotid-femoral pulse wave velocity. The other outcome measures are: systemic hemodynamics (systolic, diastolic, mean and pulse blood pressures, heart rate, cardiac output, left ventricular ejection fraction, systemic vascular resistances), central hemodynamics (aortic systolic, diastolic, mean and pulse pressures, and augmentation index), thenar tissue oxygen saturation, biological makers of inflammation (plasma fibrinogen, C-reactive protein, interleukin-6, matrix metalloproteinases -2, -9, tissue inhibitor of metalloproteinase 1), and plasma catecholamine concentrations (epinephrine, norepinephrine).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In a model of acute inflammation induced by salmonella typhi vaccination in healthy volunteers, it has been shown that acute systemic inflammation increased arterial stiffness. Since increased arterial stiffness (assessed by carotid-femoral pulse wave velocity) is an independent prognosis marker of cardiovascular risk in many chronic diseases such as hypertension, renal failure or diabetes mellitus, it could also be a marker of severity in acute inflammation states. Severe sepsis is a leading cause of hospitalisation in intensive care units, and constitutes a state of acute inflammation. It remains however to confirm that arterial stiffness is increased in this clinical conditions before evaluating its prognosis value.

This study aims to assess the effect of severe sepsis on arterial stiffness and microcirculation. Patients with severe sepsis will be compared with age-, sex- and cardiovascular risk factors-matched controls.

The primary outcome is the carotid-femoral pulse wave velocity. The other outcome measures are: systemic hemodynamics (systolic, diastolic, mean and pulse blood pressures, heart rate, cardiac output, left ventricular ejection fraction, systemic vascular resistances), central hemodynamics (aortic systolic, diastolic, mean and pulse pressures, and augmentation index), thenar tissue oxygen saturation, biological makers of inflammation (plasma fibrinogen, C-reactive protein, interleukin-6, matrix metalloproteinases -2, -9, tissue inhibitor of metalloproteinase 1), and plasma catecholamine concentrations (epinephrine, norepinephrine).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Sepsis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

acute systemic inflammation arterial stiffness Carotid-femoral pulse wave velocity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

severe sepsis

patients with severe sepsis

NA : non interventional study

Intervention Type OTHER

NA : non interventional study

Controls

Controls matched to patients on age, sex and cardiovascular risk factors

NA : non interventional study

Intervention Type OTHER

NA : non interventional study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NA : non interventional study

NA : non interventional study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Control group :

* male or female aged at least 18 years, matched on age, sex and cardiovascular risk factors (smoking, hypertension, diabetes and treated dyslipidemia) with septic patients
* Normal clinical examination and normal 12-lead ECG
* Routines biological tests in the normal range of the laboratories.
* Body mass index between 18 and 27 kg/m²
* Written informed consent
* Patients group :

* Male or female aged at least 18 years
* Severe sepsis defined by the presence of:

* a systemic inflammatory response syndrome
* the evidence of an infection
* the presence of at least one organ failure or signs of tissue hypoperfusion.
* Body mass index between 18 and 27 Kg/m²
* Written informed consent from the patients or their relatives

Exclusion Criteria

* Control group :

* legal protection or persons deprived of liberty
* bacterial or viral infection in the month preceding inclusion
* current medication
* pregnancy or breastfeeding
* exclusion period stated on the national register for persons who participate to biomedical research
* Patients group :

* legal protection or persons deprived of liberty
* vasopressor therapy
* bacterial or viral infection in the month preceding inclusion
* known cardiomyopathy
* pregnancy or breastfeeding
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rennes University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bruno LAVIOLLE, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Rennes University Hospital

Eric BELLISSANT, MD, PhD

Role: STUDY_CHAIR

Rennes University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de Réanimation Chirurgicale - Hôpital de Pontchaillou

Rennes, , France

Site Status

Unité d'Investigation Clinique - Hôpital de Pontchaillou

Rennes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010-A00612-37

Identifier Type: -

Identifier Source: org_study_id